Detail akcie Bright Minds Rg online

Business Summary: Bright Minds Biosciences Inc. is a biotechnology company, which is engaged in developing treatments for patients with neurological and psychiatric disorders. The Company is focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders. Its Serotonin (5-HT) is a neurotransmitter in the brain and modulates many biological functions. Dysfunction of serotonin receptors, transporters, and associated neurocircuits is fundamental to many diseases including epilepsies and neuro psychiatric. Its pipeline includes BMB-101, BMB-xxx, BMB-201, and BMB-202. The Company has a portfolio of patented, selective serotonin (5-HT2C, 5-HT2A and 5-HT2C/A-receptor subtypes) agonists that were identified by using high-throughput screening methods in combination with advanced molecular modeling techniques to interrogate the interaction between the drug and its targeted receptors to increase downstream signaling.
Financial Summary: BRIEF: For the fiscal year ended 30 September 2025, Bright Minds Biosciences Inc revenues was not reported. Net loss increased from C$2.8M to C$12.2M. Higher net loss reflects Stock-based Compensation in R&D increase from C$298K to C$2.6M (expense), Salary and subcontractors increase from C$1.2M to C$2.9M (expense), Office and administrative - Balancing va increase from C$182K to C$671K (expense).